Madrigal Pharmaceuticals, Inc. Common Stock
MDGL
$534.16
-1.28%
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing Rezdiffra (resmetirom), a first-in-class oral thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. As the first and only approved therapy for MASH, Madrigal holds a pioneering position in a potentially large market, but faces the challenge of establishing commercial infrastructure and competing with future entrants. The current investor narrative centers on the drug's commercial ramp, revenue growth trajectory, and the path to profitability, with recent quarterly results showing strong sales growth but continued net losses, fueling debate over the sustainability of its valuation and the timing of margin inflection.…
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
$534.16
Related headlines
Investment Opinion: Should I buy MDGL Today?
Based on the analysis, MDGL is rated a Buy, as the first-mover advantage in MASH, rapid revenue growth, and strong analyst support (average target $678.06, 25.3% upside) outweigh the risks of losses and high valuation. The thesis is that Rezdiffra's commercial success will drive revenue growth and margin expansion, leading to profitability and stock appreciation. Supporting evidence includes Q1 2026 revenue growth of 126.8% YoY, gross margin of 94.1%, narrowing net losses, and a strong balance sheet with a current ratio of 4.01. The stock's P/S of 13.63x is high but justified by the growth trajectory, and the forward P/E of 56.22x implies a profitable future.
Sign up to view all
MDGL 12-Month Price Forecast
The AI assessment is bullish with medium confidence, as the strong revenue growth and first-mover advantage are balanced by the high valuation and cash burn. The company's path to profitability is the key driver, and if revenue growth continues at a robust pace, the stock is likely to appreciate. However, the high P/S ratio and negative cash flow warrant caution, and any signs of growth deceleration would lead to a downgrade to neutral. The stance would be upgraded to high confidence if the company achieves positive free cash flow or if revenue growth reaccelerates above 150% YoY.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Madrigal Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $678.06 and implied upside of +26.9% versus the current price.
Average Target
$678.06
0 analysts
Implied Upside
+26.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$543 - $962
Analyst target range
Madrigal is covered by 16 analysts, with a consensus recommendation leaning bullish, as evidenced by recent actions from firms like Truist (Buy), Evercore ISI (Outperform), and Canaccord Genuity (Buy), though B of A Securities maintains a Neutral stance. The average analyst target price is $678.06, implying a 25.3% upside from the current price of $541.08, indicating that the Street sees further appreciation potential. The target price range is wide, from a low of $543.00 (just above the current price) to a high of $962.00, reflecting significant uncertainty about the drug's peak sales potential and competitive dynamics. The low target suggests that even the most bearish analyst sees limited downside, while the high target implies a doubling of the stock price, likely assuming faster-than-expected market penetration and successful expansion into earlier stages of MASH. The recent ratings actions have been predominantly reaffirmations of existing bullish stances, with no downgrades, signaling continued confidence in the company's commercial execution, but the wide spread in targets highlights the high-risk, high-reward nature of this investment.
Bulls vs Bears: MDGL Investment Factors
Madrigal presents a compelling growth story as the first approved MASH therapy, with rapid revenue growth and high gross margins, but the bull case is tempered by persistent losses, negative cash flow, and a premium valuation. The bear case centers on the sustainability of growth and the risk of competitive entry, while the bull case relies on continued commercial execution and margin improvement. Currently, the bull case has stronger evidence given the strong analyst support and first-mover advantage, but the most critical tension is whether revenue growth can reaccelerate and lead to profitability before competition intensifies. The stock's future hinges on the balance between scaling sales and controlling costs, which will determine if the premium valuation is justified.
Bullish
- First-to-market MASH therapy with rapid revenue growth: Rezdiffra is the first and only approved MASH treatment, generating Q1 2026 revenue of $311.3M, a 126.8% YoY increase from $137.3M in Q1 2025. This first-mover advantage in a high unmet need market underpins the growth narrative.
- High gross margin of 94.1%: Q1 2026 gross margin was 94.1%, typical for specialty pharma with a proprietary product. This strong profitability at the gross level provides a solid foundation for future operating leverage as sales scale.
- Narrowing net losses and improving operating efficiency: Net loss improved from -$114.2M in Q3 2025 to -$94.4M in Q1 2026, while operating margin improved from -39.7% to -31.3% over the same period. This trend indicates the company is moving toward profitability as revenue grows.
- Strong analyst support with 25.3% upside: The average analyst target price is $678.06, implying a 25.3% upside from the current price of $541.08. Recent actions from Truist, Evercore ISI, and Canaccord Genuity reaffirm Buy ratings, with no downgrades.
Bearish
- Persistent operating losses and negative free cash flow: Despite revenue growth, Q1 2026 operating margin was -31.3% and free cash flow was -$171.3M, with TTM FCF of -$272.4M. The company is still burning significant cash, requiring external financing to sustain operations.
- Premium valuation leaves little room for error: P/S ratio of 13.63x is over 170% above the biotech industry average of ~5.0x. This premium pricing implies high growth expectations, and any miss in commercial execution could trigger a sharp de-rating.
- Revenue growth decelerating from launch spike: Sequential revenue declined from $321.1M in Q4 2025 to $311.3M in Q1 2026, a -3.1% drop. While YoY growth remains strong, the deceleration suggests the initial launch surge is fading, raising questions about sustainable growth.
- Competitive threats from future MASH entrants: As the first mover, Madrigal will face competition from other MASH therapies in development. The wide analyst target range (low $543, high $962) reflects uncertainty about peak sales and market share erosion.
MDGL Technical Analysis
Madrigal's stock has demonstrated a robust long-term uptrend, with a 1-year price change of +25.48%, significantly outperforming the S&P 500's +18.65% over the same period. The current price of $541.08 sits at approximately 62% of the 52-week range (low: $393.61, high: $615.00), indicating a mid-range position that suggests neither overextension nor capitulation. This positioning implies the market is balancing optimism about the drug's commercial potential against concerns about competition and profitability, resulting in a consolidation phase after a strong rally from the lows.
Beta
-0.99
-0.99x market volatility
Max Drawdown
-29.4%
Largest decline past year
52-Week Range
$394-$615
Price range past year
Annual Return
+17.7%
Cumulative gain past year
| Period | MDGL Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | -0.9% |
| 3m | +13.3% | +5.6% |
| 6m | +21.8% | +15.0% |
| 1y | +17.7% | +18.1% |
| ytd | -10.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDGL Fundamental Analysis
Revenue has grown exponentially since the launch of Rezdiffra, with Q1 2026 revenue of $311.3 million, representing a 126.8% year-over-year increase from $137.3 million in Q1 2025. Sequential growth remains robust, with Q4 2025 revenue of $321.1 million and Q3 2025 at $287.3 million, indicating a deceleration from the initial launch spike but still strong double-digit growth. The company's gross margin is exceptionally high at 94.1% (Q1 2026), typical for a specialty pharmaceutical with a proprietary product, but operating margin remains deeply negative at -31.3%, reflecting heavy investment in sales, marketing, and R&D. Net income for Q1 2026 was -$94.4 million, an improvement from -$114.2 million in Q3 2025, but the company remains unprofitable, with EPS of -$3.25. The trajectory toward profitability is positive, as losses are narrowing relative to revenue, but the company is still burning cash, with free cash flow of -$171.3 million in Q1 2026 and -$272.4 million on a trailing twelve-month basis. The balance sheet shows a current ratio of 4.01, indicating strong liquidity, and a debt-to-equity ratio of 0.59, which is manageable, but the company's reliance on external financing is evident from its history of capital raises, as it has yet to generate positive cash flow from operations.
Quarterly Revenue
$311337000.0B
2026-03
Revenue YoY Growth
+126.8%
YoY Comparison
Gross Margin
91.4%
Latest Quarter
Free Cash Flow
$-272413000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDGL Overvalued?
Given that Madrigal has negative net income, the price-to-sales (P/S) ratio is the most appropriate valuation metric, and at 13.63x trailing sales, it reflects the market's high expectations for future growth. The forward P/E ratio of 56.22x, based on estimated EPS of $57.08 for the next fiscal year, implies a dramatic swing to profitability, which is a bold assumption given the current loss-making status. Compared to the biotechnology industry average P/S of approximately 5.0x, Madrigal trades at a significant premium of over 170%, which is justified by its first-mover advantage in MASH and rapid revenue growth, but leaves little room for error. Historically, the stock's P/S ratio has ranged from as low as 0x (pre-revenue) to over 400x in early 2024, and the current 13.63x is near the lower end of its post-launch range, suggesting that the market has already priced in a more mature growth trajectory, potentially offering a more reasonable entry point for long-term investors.
PE
-45.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, as Madrigal continues to report net losses, with Q1 2026 net income of -$94.4M and EPS of -$3.25. The company's operating margin of -31.3% and negative free cash flow of -$171.3M in Q1 2026 indicate heavy cash burn, though the current ratio of 4.01 provides near-term liquidity. However, the reliance on external financing is evident from the debt-to-equity ratio of 0.59 and history of capital raises, and the company must achieve profitability before cash reserves deplete. Revenue concentration in a single product, Rezdiffra, adds risk, as any setback in its commercial launch or reimbursement could severely impact financials.
FAQ
The key risks are financial, competitive, and macro-related. Financially, the company is still loss-making, with a net loss of -$94.4M in Q1 2026 and negative free cash flow of -$171.3M, which could lead to dilution. Competitively, future MASH therapies could erode market share, and the wide analyst target range reflects this uncertainty. Macro risks include sector rotation and high volatility, as evidenced by the -29.36% max drawdown. The most severe risk is a growth stall, which could lead to a -27% decline to the 52-week low.
The 12-month forecast is bullish, with a base case target of $600-$700 (50% probability), a bull case target of $700-$962 (30% probability), and a bear case target of $400-$543 (20% probability). The most likely scenario is the base case, which assumes continued revenue growth and narrowing losses. The stock is expected to trade around the analyst average target of $678.06, implying a 25.3% upside. The key assumption is that Rezdiffra's commercial ramp continues successfully, driving revenue growth and margin improvement.
MDGL is overvalued relative to the biotech industry average, with a P/S ratio of 13.63x versus the industry average of ~5.0x. This premium reflects the market's high expectations for growth, as the company is the first to market in MASH. The forward P/E of 56.22x implies a dramatic swing to profitability, which is a bold assumption. However, the stock is trading near the lower end of its post-launch P/S range, suggesting that the market has already priced in a more mature growth trajectory. The valuation implies that investors expect continued strong revenue growth and a path to profitability.
MDGL is a good buy for investors with a high risk tolerance and a long-term horizon, given its first-mover advantage in MASH and strong revenue growth. The analyst average target of $678.06 implies a 25.3% upside, but the stock is volatile and trades at a premium valuation. The biggest downside risk is a growth stall or competitive entry, which could lead to a -27% decline to the 52-week low. For those who believe in the long-term potential of Rezdiffra, the stock offers a compelling risk/reward, but it is not suitable for risk-averse investors.
MDGL is more suitable for long-term investment, as the company is in a growth phase and not yet profitable. The stock is highly volatile, with a beta of -0.99 and a max drawdown of -29.36%, making it risky for short-term trading. However, for long-term investors who believe in the MASH market's potential, the stock offers significant upside. A minimum holding period of 3-5 years is recommended to allow the company to achieve profitability and realize the full value of Rezdiffra. Short-term traders may find opportunities, but they should be prepared for high volatility.